Total Funding
82
50
Total FundingSeries C raised
Growth Score
-7 pts
Heat Score
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
14803
Electra Therapeutics is a clinical-stage biotechnology company developing antibody therapies for immunological diseases and cancer.
- Graham Parry: CSOPast Role: iPierian, Senior Director of Translational Research
- Kim-Hien Dao: Chief Medical Officer
About the Company
Electra Therapeutics focuses on developing therapies that target the Signal Regulatory Protein (SIRP) family of receptors on immune cells. The company's portfolio of SIRP-directed antibodies is designed to address the underlying pathology across a range of diseases by selectively depleting pathological immune cells. The lead product candidate,
ELA026, is a monoclonal antibody currently in pivotal clinical development for the treatment of secondary hemophagocytic lymphohistiocytosis (sHLH), a severe hyperinflammatory condition. Electra Therapeutics is also advancing a second program, ELA822, for use in immunology and inflammation conditions.
